[slide 1]
Confidentiality Notice
PRIVILEGED & CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT
Prepared by Calderwood & Harkness LLP for the Board of Directors of Optiwave Semiconductor Corp.
Not for distribution outside the Board and authorized Vantage Point Capital Partners representatives
[slide 2]
Agenda
Markman Order Summary — February 17, 2023 Ruling
Patent-by-Patent Impact Assessment
Infringement Theory Viability Post-Markman
Litigation Value Analysis: Pre- vs. Post-Markman
Financial Summary: Spend to Date and Remaining Budget
Cost-Benefit Analysis: Continue vs. Settle
Recommendation and Requested Board Action
[slide 3]
Case Background and Posture
Complaint filed June 3, 2022 asserting four patents: U.S. Patent Nos. 10,234,567; 10,891,234; 11,045,678; and 11,312,890
Accused products: LumosBridge™ 800G Optical Engine and LumosEdge™ 400ZR+ Pluggable Transceiver
Combined accused product revenue (CY 2022): ~$148.6 million
Original damages claim: in excess of $75 million (7.5% reasonable royalty + willfulness enhancement)
Markman hearing held January 30, 2023 — 6.5-hour hearing; 11 disputed claim terms across four patents
Markman Order issued February 17, 2023 — 34-page order
[slide 4]
Markman Order: Top-Line Results
Court construed all 11 disputed claim terms
Result: 8 of 11 terms — Court adopted Defendant's proposed construction or substantially Defendant-aligned construction
2 of 11 terms — Court adopted Plaintiff's proposed construction
1 of 11 terms — Court adopted a modified construction (neither party's verbatim proposal)
Net effect: Substantially narrowed the scope of all four asserted patents
Critical finding: The narrowed constructions effectively exclude the specific design choices implemented in Lumos's accused products
[slide 5]
Impact on the '567 Patent — Waveguide Coupler
Asserted Claims: 1, 4, 7, 12, and 15
Critical disputed term: 'adiabatically coupled'
OWS proposed: 'coupled such that optical mode transitions occur without significant power loss'
Court adopted: 'coupled through a gradual, continuous taper designed and configured to prevent excitation of higher-order modes over the entire transition length'
Lumos's LumosBridge™ uses a segmented (non-continuous) taper with discrete coupling sections
Assessment: Infringement theory is UNTENABLE under the Court's construction
[slide 6]
Impact on the '234 Patent — Germanium Photodetector
Asserted Claims: 1, 3, 5, 8, and 11
Critical disputed term: 'graded buffer layer having a continuously varying germanium concentration'
OWS proposed: 'a buffer layer in which the germanium concentration changes across the layer thickness'
Court adopted (Defendant's verbatim): 'a buffer layer in which the germanium atomic fraction increases monotonically and without step changes from the silicon substrate interface to the absorber layer'
Lumos uses a step-graded SiGe buffer with four discrete composition steps (Ge fractions: 0.25, 0.50, 0.75, 1.0)
Assessment: Infringement theory is UNTENABLE — step-graded design is explicitly excluded
[slide 7]
Impact on the '678 Patent — Multi-Channel Transceiver / WDM
Asserted Claims: 1, 2, 6, 9, and 14
Critical disputed term: 'integrated wavelength-division multiplexing element monolithically formed on a single silicon die'
OWS proposed: 'a WDM component fabricated as part of the same semiconductor fabrication process on a single die'
Court adopted: 'fabricated entirely within the same FEOL and BEOL semiconductor processing sequence on a single silicon substrate without heterogeneous bonding or attachment of separately fabricated optical components'
Lumos's 800G platform uses micro-transfer-printed III-V gain elements bonded to the silicon PIC — a heterogeneous integration approach
Assessment: Infringement theory is UNTENABLE under the Court's construction
[slide 8]
Impact on the '890 Patent — Driver Circuit Architecture
Asserted Claims: 1, 5, 8, and 13
Critical disputed term: 'pre-emphasis equalization stage electrically co-integrated with the modulator on a common substrate'
OWS proposed: 'an equalization circuit located on the same substrate as the modulator'
Court adopted (Defendant's verbatim): 'fabricated in the same semiconductor process, sharing doping profiles and process layers, without bond wires, interposers, or package-level routing'
Lumos uses a separate CMOS driver die flip-chip bonded via copper pillar micro-bumps to the silicon photonic modulator die
Assessment: Infringement theory SIGNIFICANTLY WEAKENED — some theoretical DOE arguments remain but are weak
[slide 9]
Summary: Infringement Viability Across All Four Patents
'567 Patent (Waveguide Coupler): UNTENABLE — segmented taper excluded by 'adiabatically coupled' construction
'234 Patent (Ge Photodetector): UNTENABLE — step-graded buffer excluded by 'continuously varying' construction
'678 Patent (WDM/Transceiver): UNTENABLE — heterogeneous integration excluded by 'monolithically formed' construction
'890 Patent (Driver Circuit): SIGNIFICANTLY WEAKENED — flip-chip bonding excluded; only theoretical DOE arguments remain (<5% trial success probability)
Overall assessment: Infringement theories are untenable as to three of four patents and significantly weakened as to the fourth
[slide 10]
Pre-Markman vs. Post-Markman Litigation Value
Pre-Markman claimed damages: >$75 million (reasonable royalty + willfulness enhancement)
Pre-Markman expected recovery (risk-adjusted): ~$22–30 million (30–40% probability of favorable outcome at trial)
Post-Markman expected recovery (risk-adjusted): <$1 million (<5% probability on remaining '890 Patent DOE theory; reduced damages base)
Pre-litigation patent valuation (four asserted patents, per Clearpath IP Valuation Services): $42.8 million
Post-Markman impairment: The narrow claim constructions materially impair the enforcement value of all four patents — even against future defendants
Broader portfolio impact: The 87-patent portfolio valuation ($215 million) may require reassessment in light of narrowed claim scope on core technology patents
[slide 11]
Financial Summary: Litigation Spend to Date
Board-approved litigation budget (through trial): $4.2 million
Calderwood & Harkness fees billed to date: ~$1.55 million (est. through Feb. 2023)
Calderwood & Harkness costs/disbursements to date: ~$230,000 (est.)
Expert fees to date (Whitfield Technical Consulting + Apex Claim Analytics): ~$350,000 (est.)
Estimated total spend to date: ~$2.1 million
Remaining budget (if proceeding through trial): ~$2.1 million
Retainer deposits to date: $300,000 (3 quarters × $100,000); Q1 2023 replenishment pending
[slide 12]
Cost-Benefit Analysis: Continue Litigation vs. Settle
Scenario A — Continue Through Trial:
• Estimated remaining cost: ~$1.65 million (fact discovery completion, expert reports, depositions, Daubert motions, summary judgment, pre-trial, trial)
• Expected recovery: <$1 million (probability-weighted)
• Net expected value: NEGATIVE (~-$650,000 to -$1.6 million)
Scenario B — Negotiate Settlement Now:
• Incremental cost: $50,000–$100,000 (settlement negotiation and documentation)
• Most likely settlement range: $0 (walk-away with mutual releases) given weakened leverage
• Sunk cost savings preserved; no additional risk
Recommendation: Scenario B is the economically rational path
[slide 13]
Settlement Posture and Negotiation Strategy
Initial OWS proposal: Cross-license covering full patent portfolios with nominal royalty payment from Lumos
Fallback position: Walk-away settlement — mutual general releases, $0 payment, each side bears own costs, dismissal with prejudice
Key terms to negotiate: Scope of releases, whether any cross-license or covenant not to sue is included, no admission of infringement/validity/invalidity
Timeline: Propose 30-day settlement discussion window with stipulated discovery stay to avoid further cost accrual
Counterparty dynamics: Lumos (Nasdaq: LMPH, market cap ~$2.2 billion) has strong leverage post-Markman but also incentive to resolve quickly to eliminate litigation overhang
[slide 14]
Implications for OWS's IP Strategy Going Forward
Patent prosecution lessons: Narrow claim amendments during prosecution created estoppel vulnerabilities exploited at Markman
Portfolio reassessment: Recommend engaging Clearpath IP Valuation Services to update the portfolio valuation reflecting narrowed claim scope
Future enforcement: The four asserted patents have diminished enforcement value against any competitor using industry-standard design approaches (segmented tapers, step-graded buffers, heterogeneous integration, flip-chip bonding)
Lender notification: First Pacific Commerce Bank must be notified of litigation resolution given IP collateral interest under the $40 million credit facility
No impact on OWS product lines: OWS's own products (OWS-400ZR, OWS-800LR) fabricated at Pinnacle Semiconductor Foundry on 45nm SOI remain unaffected
[slide 15]
Recommendation and Requested Board Action
RECOMMENDATION: Authorize settlement discussions with Lumos Photonics
Primary objective: Negotiate a cross-license with nominal royalty payment
Authorized fallback: Accept walk-away settlement (mutual releases, $0, each side bears own costs, dismissal with prejudice)
Settlement authority requested: Approval to settle on terms within the walk-away to cross-license-with-nominal-royalty range
Vantage Point concurrence requested: Douglas Fairbanks III and Rebecca Torres to confirm Vantage Point's alignment with settlement authority
Next steps upon authorization: Alan Ngo to contact opposing counsel within one week to initiate discussions; request stipulated discovery stay
[slide 16]
Appendix A: Markman Order — Claim Construction Summary Table
| Patent | Disputed Term | OWS Proposed | Lumos Proposed | Court's Construction | Prevailing Party |
| '567 — 'adiabatically coupled' | OWS: no significant power loss | Lumos: gradual continuous taper preventing higher-order modes | Court: gradual continuous taper (Def. w/ mod.) | Lumos | |
| '234 — 'continuously varying germanium concentration' | OWS: changes across thickness | Lumos: monotonically without step changes | Court: Def. verbatim | Lumos | |
| '678 — 'monolithically formed on a single silicon die' | OWS: same fab process on single die | Lumos: same FEOL/BEOL, no heterogeneous bonding | Court: largely Def. | Lumos | |
| '890 — 'co-integrated...on a common substrate' | OWS: on same substrate | Lumos: same process, shared doping, no bond wires/interposers | Court: Def. verbatim | Lumos |
[Plus 7 additional terms — 4 resolved for Lumos, 2 for OWS, 1 modified]
[slide 17]
Appendix B: Litigation Timeline
March 15, 2022 — Cease-and-desist letter sent to Lumos
April 28, 2022 — Board authorizes litigation; Vantage Point concurs
May 12, 2022 — Calderwood & Harkness engagement letter executed
June 3, 2022 — Complaint filed (Case No. 5:22-cv-03417-EJD, N.D. Cal.)
July 29, 2022 — Lumos files Answer and Counterclaims (non-infringement, invalidity under §§ 102, 103, 112)
September–October 2022 — Claim construction contentions exchanged; discovery completed
December 2022–January 2023 — Claim construction briefs filed
January 30, 2023 — Markman Hearing (6.5 hours)
February 17, 2023 — Markman Order issued
February 24, 2023 — THIS MEETING
[slide 18]
Appendix C: Financial Detail — Spend to Date and Budget Forecast
Board-approved budget: $4.2 million through trial
C&H fees to date (est. through Feb. 2023): ~$1.55 million
C&H costs/disbursements to date: ~$230,000
Expert fees — Dr. Harold Whitfield (technical expert): ~$250,000 (est.)
Expert fees — Dr. Lawrence Kessler (damages expert, Apex Claim Analytics): ~$100,000 (est.)
Total estimated spend to date: ~$2.1 million (~50% of budget consumed)
Remaining budget if proceeding to trial: ~$2.1 million
Estimated incremental cost of settlement negotiation and documentation: $50,000–$100,000